Skip to main content
Frontiers in Medicine logoLink to Frontiers in Medicine
. 2026 Feb 20;13:1789363. doi: 10.3389/fmed.2026.1789363

Correction: Factors influencing therapeutic efficacy of non-lactational mastitis based on hematological inflammatory markers and establishment of a predictive model

Jinjuan Peng 1, Li Li 1, Lili Fan 1, Qun Lu 2,*
PMCID: PMC12964699  PMID: 41797762

Affiliation “Department of Breast Surgery, The Fourth People's Hospital of Zhenjiang, The Fourth Affiliated Hospital of Jiangsu University, Zhenjiang, China” was erroneously given as “Department of Breast Surgery, The Fourth Affiliated Hospital of Jiangsu University, Zhenjiang, China.”

There was a mistake in Table 2 as published. There were data errors and missing values in the Good efficacy group (n = 133) column in Table 2.

Table 2.

Univariate analysis of factors influencing therapeutic efficiency of NLM.

Baseline data Poor efficacy group (n = 52) Good efficacy group (n = 133) t/χ2 Value p-Value
Age (years) 35.96 ± 5.46 35.23 ± 5.40 0.824 0.411
Number of pregnancies < 2 31 (59.62) 75 (56.39) 0.159 0.690
≥2 21 (40.38) 58 (43.61)
Menstrual disorders Yes 33 (63.46) 85 (63.91) 0.003 0.955
No 19 (36.54) 48 (36.09)
Overweight/obesity Yes 22 (42.31) 36 (27.07) 4.034 0.045
No 30 (57.69) 97 (72.93)
History of lactational mastitis Yes 16 (30.77) 43 (32.33) 0.042 0.838
No 36 (69.23) 90 (67.67)
History of hyperprolactinemia Yes 15 (28.85) 40 (30.08) 0.027 0.869
No 37 (71.15) 93 (69.92)
History of breast trauma Yes 11 (21.15) 24 (18.05) 0.236 0.628
No 41 (78.85) 109 (81.95)
Abscess formation Yes 40 (76.92) 101 (75.94) 0.020 0.888
No 12 (23.08) 32 (24.06)
Sinus tract formation Yes 10 (19.23) 21 (15.79) 0.317 0.573
No 42 (80.77) 112 (84.21)
History of hormone therapy Yes 6 (11.54) 11 (8.27) 0.478 0.489
No 46 (88.46) 122 (91.73)
SII 200.01 ± 23.30 130.32 ± 27.79 16.010 < 0.001
PCT (ng/L) 0.60 ± 0.04 0.59 ± 0.05 1.289 0.199
CRP (mg/L) 26.95 ± 2.04 21.81 ± 4.07 8.680 < 0.001

IL-8, interleukin-8; PCT, procalcitonin; IL-6, interleukin-6; CRP, C-reactive protein.

The corrected Table 2 appears below.

The original version of this article has been updated.

Footnotes

Edited and reviewed by: Muneeb A. Faiq, New York University, United States

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.


Articles from Frontiers in Medicine are provided here courtesy of Frontiers Media SA

RESOURCES